CDSCO (India)
REGULATION
2026.06.11 S.O. 3068(E) to S.O. 3083(E)_ Prohibition of 16 FDC's
Published: 6/11/2026Detected: 6/22/2026
Summary preview
Prohibits 16 fixed-dose combination (FDC) drug products under India’s CDSCO regulatory framework, which may remove certain therapies from the market and block related manufacturing/marketing authorizations.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountOfficial Source Document Source Verified
Access the original document directly from INDIA CDSCO.
More from CDSCO (India)
- Indiscriminate use of painkillers (NSAIDs), antibiotics and associated risk of Chronic Kidney Disease9/22/2026
- LIST OF REGISTRED BA-BE STUDY CENTRE & BIO-ANALYTICAL LABORATORY under NDCT Rules 20199/18/2026
- Public Health alert against the use of unauthorised Cosmetics Products9/14/2026
- 2026.09.08 G.S.R. 791(E)_Draft notification for amendment in the Drugs Rules 1945 regarding mandatory installation of CCTV surveillance system at sales premises9/8/2026
- Drug Regulatory and Law Enforcement Agencies Intensify Coordinated Action Against Illegal Manufacture and Distribution of Misbranded Drugs9/5/2026